Association of Frailty, Age, and Biological Sex With Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine–Induced Immunity in Older Adults

Abstract Background Male sex and old age are risk factors for severe coronavirus disease 2019, but the intersection of sex and aging on antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines has not been characterized. Methods Plasma samples were collected from o...

Full description

Saved in:
Bibliographic Details
Published inClinical infectious diseases Vol. 75; no. Supplement_1; pp. S61 - S71
Main Authors Shapiro, Janna R, Sitaras, Ioannis, Park, Han Sol, Aytenfisu, Tihitina Y, Caputo, Christopher, Li, Maggie, Lee, John, Johnston, Trevor S, Li, Huifen, Wouters, Camille, Hauk, Pricila, Jacobsen, Henning, Li, Yukang, Abrams, Engle, Yoon, Steve, Kocot, Andrew J, Yang, Tianrui, Huang, Yushu, Cramer, Steven M, Betenbaugh, Michael J, Debes, Amanda K, Morgan, Rosemary, Milstone, Aaron M, Karaba, Andrew H, Pekosz, Andrew, Leng, Sean X, Klein, Sabra L
Format Journal Article
LanguageEnglish
Published United States Oxford University Press 15.08.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Abstract Background Male sex and old age are risk factors for severe coronavirus disease 2019, but the intersection of sex and aging on antibody responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines has not been characterized. Methods Plasma samples were collected from older adults (aged 75–98 years) before and after 3 doses of SARS-CoV-2 mRNA vaccination, and from younger adults (aged 18–74 years) post-dose 2, for comparison. Antibody binding to SARS-CoV-2 antigens (spike protein [S], S receptor-binding domain, and nucleocapsid), functional activity against S, and live-virus neutralization were measured against the vaccine virus and the Alpha, Delta, and Omicron variants of concern (VOCs). Results Vaccination induced greater antibody titers in older females than in older males, with both age and frailty associated with reduced antibody responses in males but not females. Responses declined significantly in the 6 months after the second dose. The third dose restored functional antibody responses and eliminated disparities caused by sex, age, and frailty in older adults. Responses to the VOCs, particularly the Omicron variant, were significantly reduced relative to the vaccine virus, with older males having lower titers to the VOCs than older females. Older adults had lower responses to the vaccine and VOC viruses than younger adults, with greater disparities in males than in females. Conclusions Older and frail males may be more vulnerable to breakthrough infections owing to low antibody responses before receipt of a third vaccine dose. Promoting third dose coverage in older adults, especially males, is crucial to protecting this vulnerable population. Severe acute respiratory syndrome coronavirus 2 messenger RNA vaccination induces greater antibody response in older females than in older males. Age and frailty reduce responses only in males. These effects are eliminated by a third vaccine dose, highlighting the need for third dose coverage, especially in older males.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Sean X Leng and Sabra L Klein contributed equally to this work.
Potential conflicts of interest. I. S., M. L., C. W., S. Y., and A. P. received funding for their institution from NIAID/NIH (grants N272201400007C and 75N93021C00045) and from the CDC (grant 75D30121C11061). A. J. K., S. M. C., and M. J. B. received grant support from the National Institute for Innovation in Manufacturing Biopharmaceuticals consortium, which that went to their institution. R. M. was supported by the Office of Research on women's Health and the NIA, NIH (grant U54AG062333). A. M. M. has received grants or contracts from the Agency for Healthcare Research and Quality, the CDC, the NIH, and Merck. A. H. K. received NIAID funding (grant K08AI156021) and consulting fees from Roche. S. X. L. received NIH grants for their institution (grants U54AG062333, R01AI108907, R21AG059742, UH2AG056933, U01AI35042, R01AG060825, and U01AI165826); funding for their institution from Cybersecurity and Infrastructure Security Agency, MMAAP, the Sanofi Pasteur grant project and the Howard and Abby Milstein Foundation; and honoraria for participating in the Sanofi Pasteur COVID-19 Vaccine International Advisory Board, the Sanofi Pasteur Speakers Bureau for Influenza Vaccines, and the GSK Speakers Bureau for Herpes Zoster Vaccine Shingrix. They are also the president of the MMAAP foundation. S. L. K. received support from the NIA/NIH (grant U54AG062333) and NIH/National Cancer Institute/NIH (grant U54CA260492) and is a board member for the NIH’s Advisory Committee on Research on women's Health and an editor for PloS Pathogens and the Journal of Virology. All other authors report no potential conflicts.
ISSN:1058-4838
1537-6591
1537-6591
DOI:10.1093/cid/ciac397